Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the transaction, the senior vice president owned 213,476 shares of the company’s stock, valued at $3,635,496.28. The trade was a 5.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Price Performance

Theravance Biopharma stock traded up $0.01 during mid-day trading on Thursday, hitting $17.04. 306,932 shares of the company’s stock traded hands, compared to its average volume of 556,140. Theravance Biopharma, Inc. has a fifty-two week low of $13.08 and a fifty-two week high of $21.03. The stock has a market cap of $884.70 million, a price-to-earnings ratio of 16.87 and a beta of 0.25. The firm has a 50 day simple moving average of $16.96 and a two-hundred day simple moving average of $16.41.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%.The company had revenue of $20.73 million for the quarter, compared to analyst estimates of $22.49 million. On average, research analysts anticipate that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new stake in shares of Theravance Biopharma during the 1st quarter valued at $2,076,000. Wedge Capital Management L L P NC bought a new position in Theravance Biopharma in the second quarter valued at about $2,190,000. Precision Wealth Strategies LLC acquired a new stake in shares of Theravance Biopharma during the first quarter valued at about $1,019,000. Dimensional Fund Advisors LP increased its stake in shares of Theravance Biopharma by 14.5% in the first quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock valued at $15,960,000 after buying an additional 124,658 shares during the period. Finally, Rangeley Capital LLC acquired a new stake in Theravance Biopharma during the 1st quarter worth approximately $1,672,000. Institutional investors own 99.10% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on TBPH shares. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. Zacks Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 7th. HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and raised their price target for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. Finally, BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Eight investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, Theravance Biopharma currently has an average rating of “Hold” and an average price target of $19.40.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.